FrancophonIA/ELRC3.0 huggingface dataset:
English: While one study compared the effects of Ulunar Breezhaler with those of placebo (a dummy inhalation), or indacaterol or glycopyrronium alone, the other study compared Ulunar Breezhaler with fluticasone plus salmeterol, a standard treatment for COPD.
Maltese: Filwaqt li wieħed mill-istudju qabbel l-effetti ta' Ulunar Breezhaler ma' dawk tal-plaċebo (teħid ta' nifs finta) jew l-indakaterol jew il-glikopirronju waħdu, l-istudju l-ieħor qabbel Ulunar Breezhaler mal-flutikasone flimkien mas-salmeterol, kura standard għas-COPD. Fiż-żewġ studji, il-kejl ewlieni tal-effikaċja kien ilmod li bih Ulunar Breezhaler tejjeb il-volumi furzati ta' nifs 'il barra tal-pazjent (FEV1, il-volum massimu ta' arja li persuna tista' toħroġ man-nifs f'sekonda) wara 26 ġimgħa ta' kura.
English: (EU) MA Number Invented name
Maltese: Numru ta' l-UE Isem kummerċjali
English: Further information on Slenyto can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Slenyto is available as tablets (1 and 5 mg).
Maltese: Slenyto jiġi bħala pilloli (1 u 5 mg).
English: The medicine contains the active substance melatonin.
Maltese: Il-mediċina fiha s-sustanza attiva melatonin.
English: Other information about Slenyto
Maltese: Informazzjoni oħra dwar Slenyto
English: The active substance in Slenyto, melatonin, is a naturally occurring hormone, which is normally produced by a gland in the brain called the pineal gland.
Maltese: Is-sustanza attiva fi Slenyto, il-melatonin, hija ormon naturali, li normalment tiġi prodotta minn glandola fil-moħħ imsejħa glandola pineal.
English: The most common side effects with Slenyto (which may affect up to 1 in 10 people) are sleepiness, tiredness, mood swings, headache, irritability, aggression and feeling hungover.
Maltese: L-effetti sekondarji l-iktar komuni bi Slenyto (li jistgħu jaffettwaw sa persuna 1 minn kull 10) huma ngħas, għeja, bidliet fil-burdata, uġigħ ta' ras, irritabilità, aggressjoni u sensazzjoni ta' hangover.
English: In a main study of 125 patients, those given Slenyto over 13 weeks slept on average for 51 extra minutes of sleep a night compared with and 19 extra minutes for those given placebo (a dummy treatment).
Maltese: Fi studju ewlieni ta' 125 pazjent, dawk li ngħataw Slenyto għal 13-il ġimgħa raqdu għal medja ta' 51 minuta żejda ta' rqad kull lejl meta mqabbel ma' 19-il minuta żejda għal dawk li ngħataw plaċebo (kura finta).
English: In addition, children who took Slenyto fell asleep around 38 minutes earlier than normal while those taking placebo fell asleep 13 minutes earlier.
Maltese: Barra minn hekk, it-tfal li ħadu Slenyto raqdu madwar 38 minuta qabel min-normal waqt li dawk li kienu qed jieħdu plaċebo raqdu 13-il minuta qabel.
English: What are the risks associated with Slenyto?
Maltese: X'inhuma r-riskji assoċjati ma' Slenyto?
English: As for all medicines, data on the use of Slenyto are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Slenyto hija ssorveljata kontinwament.
English: Slenyto has been shown to improve sleeping times in these patients, with patients taking Slenyto sleeping for an extra 51 minutes a night compared with an extra 19 minutes with placebo.
Maltese: Slenyto ntwera li jtejjeb il-ħinijiet ta' rqad f'dawn il-pazjenti, b'dawk il-pazjenti li jieħdu Slenyto jorqdu 51 minuta addizzjonali kull lejl meta mqabbla ma' dawk li jieħdu plaċebo u jorqdu 19-il minuta addizzjonali.
English: Slenyto has been shown to be effective at improving sleeping time in children and adolescents with neurological conditions, including autism spectrum disorder and Smith-Magenis syndrome.
Maltese: Slenyto wera li huwa effettiv biex itejjeb il-ħin tal-irqad fit-tfal u fl-adolexxenti b'kundizzjonijiet newroloġiċi, inkluż disturb ġeneralizzat tal-awtiżmu u s-sindromu ta' Smith-Magenis.
English: Slenyto is a medicine for treating insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old) who have:
Maltese: Slenyto huwa mediċina għall-kura tal-insomnja (diffikulta fl-irqad) fit-tfal u fl-adolexxenti (bejn sentejn u 18-il sena) li għandhom:
English: • autism spectrum disorder (ASD), a range of conditions that affects the patient's social interactions;
Maltese: • disturb fl-ispettru tal-awtiżmu (ASD), firxa ta' kundizzjonijiet li jaffettwaw l-interazzjonijiet soċjali tal-pazjent;
English: The side effects seen with the medicine over 2 years appear mild or moderate but more data are needed on longer term safety.
Maltese: L-effetti sekondarji rrappurtati bi Slenyto huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: What measures are being taken to ensure the safe and effective use of Slenyto?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Slenyto?
English: All patients had previously tried other measures, such as keeping to a regular sleeping routine, which did not work.
Maltese: Il-pazjenti kollha kienu diġà pprovaw miżuri oħrajn, eżempju jżommu ma' rutina regolari ta' rqad, li ma ħadmux.
English: Its levels in the blood normally increase after the onset of darkness and peak in the middle of the night.
Maltese: Il-livelli tagħha fid-demm normalment jiżdiedu hekk kif ifeġġ id-dlam u jkunu fl-aqwa tagħhom f'nofs ta' lejl.
English: For the full list of side effects and restrictions, see the package leaflet.
Maltese: Għallista sħiħa tal-effetti sekondarji u r-restrizzjonijiet, ara l-fuljett ta' tagħrif.
English: The doctor should review treatment regularly, at least every 6 months, and only continue treatment if the patient is benefits from it.
Maltese: It-tabib għandu jissorvelja l-kura b'mod regolari, tal-anqas kull 6 xhur, u jkompli l-kura biss jekk il-pazjent ikun qed jibbenefika minnha.
English: Why is Slenyto authorised in the EU?
Maltese: Għaliex Slenyto ġie awtorizzat fl-UE?
English: Because Slenyto releases melatonin slowly over a few hours, it mimics the natural production of melatonin in the body.
Maltese: Minħabba li Slenyto jirrilaxxa l-melatonin bil-mod tul ftit sigħat, huwa jimita l-produzzjoni naturali tal-melatonin filġisem.
English: Colistin-base activity (CBA) (mg)1
Maltese: Attività bażi-Colistin (CBA) (mg)1
English: 1 Nominal potency of the drug substance = 12.500 IU/mg
Maltese: Potenza nominali tas-sustanza = 12.500
English: Currently, products containing colistimethate sodium for use by injection or by inhalation as a solution or as a mist (nebulised) are approved under various trade names in Austria, Belgium, Bulgaria, Croatia, the Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Malta, Netherlands Poland, Portugal, Romania, Slovakia, Spain, Sweden and United Kingdom.
Maltese: Bħalissa, prodotti li fihom colistimethate sodium għal użu b'injezzjoni jew bit-teħid tannifs bħala soluzzjoni jew bħala raxx (nebulizzat) huma approvati taħt diversi ismijiet kummerċjali flAwstrija, fil-Belġju, fil-Bulgarija, fil-Kroazja, fir-Repubblika Ċeka, fid-Danimarka, fl-Estonja, fi Franza, fil-Ġermanja, fil-Greċja, fl-Ungerija, fl-Irlanda, fl-Italja, fil-Lussemburgu, f'Malta, fil-Pajjiżi l-Baxxi, filPolonja, fil-Portugall, fir-Rumanija, fis-Slovakkja, fi Spanja, fl-Isvezja u fir-Renju Unit.
English: • In children, the suggested dose is 75,000 to 150,000 IU/kg daily, in 3 divided doses.
Maltese: • Fit-tfal, id-doża rakkomandata hija 75,000 sa 150,000
English: Contact our press officer Monika Benstetter
Maltese: Ikkuntattja l-uffiċali tagħna tal-istampa Monika Benstetter
English: European Medicines Agency completes review of polymyxin-based medicines
Maltese: L-Aġenzija Ewropea għall-Mediċini tlesti reviżjoni talmediċni bbażati fuq polymyxin
English: Based on the limited available evidence the recommended dose in adults is 9 million IU daily in 2 or 3 divided doses as a slow intravenous infusion; in critically ill patients a loading dose of 9 million IU should be given.
Maltese: Abbażi tal-evidenza limitata disponibbli, id-doża rakkomandata fl-adulti hija 9 miljun IU kuljum f'2 jew 3 dożi diviżi bħala infużjoni intravenuża bil-mod; f'pazjenti morda b'mod kritiku għandha tingħata doża inizjali ta' 9 miljun IU.
English: (Products for inhalation as a dry powder have a different dosage and distribution in the body, and were not affected by the conclusions of the review.)
Maltese: (Prodotti għal teħid man-nifs bħala trab xott għandhom dożaġġ u distribuzzjoni differenti fil-ġisem, u ma ġewx affetwati mill-konklużjonijiet tar-reviżjoni.)
English: • Intravenous colistimethate sodium is indicated in adults and children including neonates for the treatment of serious infections due to aerobic Gram-negative pathogens in patients with limited treatment options.
Maltese: • Colistimethate sodium intravenuż huwa indikat f'adulti u tfal inklużi trabi tat-twelid għall-kura ta' infezzjonijiet serji minħabba patoġeni Gram-negattivi aerobiċi f'pazjenti b'alternattivi ta' kura limitati.
English: The recommended dose in adults is 1 to 2 million IU given 2 to 3 times a day, and in children 0.5 to 1 million IU twice daily, adjusted according to the severity of the condition and the response.
Maltese: Id-doża rakkomandata fl-adulti hija 1 sa 2 miljuni IU mogħtija 2 sa 3 darbiet kuljum, aġġustati skont is-severità tal-kundizzjoni u r-rispons.
English: On 23 October 2014 the European Medicines Agency (EMA) completed a review of the safety and effectiveness of products containing the antibiotics colistin or colistimethate sodium (known as polymyxins) and recommended changes to their product information to ensure safe use in the treatment of serious infections that are resistant to standard antibiotics.
Maltese: Fit-23 ta' Ottubru 2014, l-Aġenzija Ewropea għall-Mediċini (EMA) lestiet reviżjoni tas-sigurtà u leffikaċja ta' prodotti li fihom l-antibijotiċi colistin jew colistimethate sodium (magħrufin bħala polymyxins) u rrakkomandat bidliet fl-informazzjoni dwar il-prodott tagħhom biex jiġi żgurat użu sigur fil-kura ta' infezzjonijiet serji li huma reżistenti għal antibijotiċi standard.
English: Polymyxins are a group of antibiotics that includes colistin and colistimethate sodium (a ‘prodrug' that is converted to colistin in the body), which have been available in the EU since the 1960s for the treatment of susceptible infections.
Maltese: Polymyxins huma grupp ta' antibijotiċi li jinkludi colistin u colistimethate sodium (‘promediċina' li tinbidel colistin fil-ġisem), li ilhom disponibbli fl-UE sa mis-snin sittin għall-kura ta' infezzjonijiet suxxettibbli.
English: The CHMP opinion was forwarded to the European Commission, which issued a final decision valid throughout the EU on 16 December 2014.
Maltese: L-opinjoni tas-CHMP ġiet mgħoddija lillKummissjoni Ewopea, li ħarġet deċiżjoni finali valida madwar l-UE fis-16 ta' Diċembru 2014.
English: • Injection or infusion (drip) of colistimethate sodium should only be used to treat serious infections in patients with few other treatment options, normally combined with another antibiotic.
Maltese: • Injezzjoni jew infużoni (dripp) ta' colistimethate sodium għandhom jintużaw biss biex jiġu kkurati infezzjoni f'pazjenti bi ftit alternattivi ta' kura oħrajn, normalment ikkombinati ma' antibijotiku ieħor.
English: CHMP concluded that colistimethate sodium may also be given by inhalation or in a nebuliser to treat ongoing (chronic) infections with the bacterium Pseudomonas aeruginosa in patients with cystic fibrosis.
Maltese: Is-CHMP ikkonkluda li colistimethate sodium jista' jingħata wkoll permezz ta' inalazzjoni jew f'nebulizzatur biex jiġu kkurati infezzjonijiet kontinwi (kroniċi) bil-batterja Pseudomonas aeruginosa f'pazjenti b'fibrożi ċistika.
English: Recommendations issued for safe use in patients with serious infections resistant to standard antibiotics
Maltese: Rakkomandazzjonijiet maħruġa għal użu sigur f'pazjenti b'infezzjonijiet serji reżistenti għal antibijotiċi standard
English: • Doses should always be expressed in IU of colistimethate sodium.
Maltese: • Id-dożi għandhom dejjem jiġu espressi bħala IU ta' colistimethate sodium.
English: • When given by inhalation, colistimethate sodium solutions may be used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adults and children with cystic fibrosis.
Maltese: • Meta jingħata permezz ta' inalazzjoni, soluzzjonijiet ta' colistimethate sodium jistgħu jintużaw għall-ġestjoni ta' infezzjonijiet pulmonari kroniċi minħabba Pseudomonas aeruginosa f'adulti u tfal b'fibrożi ċistika.
English: • The available information on colistimethate sodium has been reviewed and recommendations have been made on its safe use and appropriate dosage.
Maltese: • L-informazzjoni disponibbli fuq colistimethate sodium ġiet riveduta u saru rakkomandazzjonijiet fuq l-użu sigur tiegħu u d-dożaġġ xieraq.
English: A parallel review under Article 5(3) of Regulation (EC) No 726/2004 is currently also under way, looking at the quality of the products and the way the potency of colistimethate sodium is measured and tested, and may result in further changes to the product information once complete.
Maltese: Bħalissa qiegħda ssir reviżjoni parallela skont Artikolu 5(3) tar-Regolament (KE) Nru 726/2004, li tħares lejn il-kwalità tal-prodotti u l-mod ta' kif il-qawwa ta‘ colistimethate sodium titkejjel u tiġi ttestjata, u tista' tirriżulta f'iktar bidliet fl-informazzjoni dwar il-prodott ladarba titlesta.
English: The review considered products given by injection or inhaled as a liquid into the lungs (systemic use) containing colistimethate sodium, which is converted to the active substance colistin in the body.
Maltese: Ir-reviżjoni kkunsidrat prodotti mogħtija b'injezzjoni jew meħudin man-nifs fil-pulmun (użu sistemiku) li fihom colistimethate sodium, li jiġi mibdul għas-sustanza attiva colistin fil-ġisem.
English: • Intravenous colistimethate sodium does not cross the blood-brain barrier to a significant extent.
Maltese: • Colistimethate sodium intravenuż ma jaqsamx il-barriera demm-moħħ sa punt sinifikanti.
English: 16 December 2014 EMA/785229/2014 corr1
Maltese: 16 ta' Diċembru 2014
English: The CHMP concluded that injection or infusion (drip) of colistimethate sodium should be reserved for the treatment of serious infections due to susceptible bacteria, in patients whose other treatment options are limited.
Maltese: Is-CHMP ikkonkluda li injezzjoni jew infużjoni (dripp) ta' colistimethate sodium għandhom jiġu riżervati għall-kura ta' infezzjonijiet serji minħabba batterji suxxettibli, f'pazjenti li għandhom alternattivi oħrajn ta' kuri limitati.
English: Colistimethate sodium may also be inhaled as a liquid vapour to treat lung infection in patients with cystic fibrosis.
Maltese: Colistimethate sodium jista' wkoll jittieħed man-nifs bħala fwar likwidu biex tiġi kkurata infezzjoni fil-pulmun f'pazjenti b'fibrożi ċistika.
English: Research currently underway may provide further information on pharmacodynamics and pharmacokinetics of these medicines to improve the evidence-base behind any dose recommendations.
Maltese: Riċerka li għaddejja bħalissa tista' tipprovdi iktar informazzjoni dwar il-farmakodinamiċi u farmakokinetiċi ta' dawn ilmediċini biex ittejjeb il-bażi ta' evidenza għal kwalunkwe rakkomandazzjoni ta' dożi.
English: In addition, colistimethate sodium has been approved in the EU for inhalation as a dry powder under the trade name Colobreathe.
Maltese: Barra minn hekk, colistimethate sodium ġie approvat fl-UE għat-teħid bin-nifs bħala trab niexef taħt l-isem kummerċjali Colobreathe.
English: To address the differences in the way in which the strength of colistimethate sodium and colistin are expressed in the EU and in other regions such as the USA and Australia, which has led to errors in reporting in the medical literature and could potentially lead to serious medication errors, the following table will be included in the product information:
Maltese: Biex jiġu indirizzati ddifferenzi fil-mod ta' kif jiġu mfissra l-qawwiet ta' colistimethate sodium sodium u colistin fl-UE u reġjuni oħrajn bħall-Istati Uniti u l-Awstralja, li wasslu għal żbalji fir-rappurtar f'letteratura medika u jista' potenzjalment iwassal għal żbalji ta' medikazzjoni serji, it-tabella li ġejja sejra tiġi inkluża fl-informazzjoni dwar il-prodott:
English: Due in part to this limited use, colistimethate sodium has retained activity against a number of bacteria which have become resistant to commonly used antibiotics.
Maltese: Minħabba parzjalment għal dan l-użu limitat, colistimethate sodium żamm l-attività tiegħu kontra numru ta' batterji li saru reżistenti għal antibijotiċi użati b'mod komuni.
English: The medicine should be given with another suitable antibiotic where possible.
Maltese: Il-mediċina għandha tingħata ma' antibijotiku ieħor xieraq meta jkun possibbli.
English: Consideration should be given to co-administration with another antibacterial agent whenever this is possible.
Maltese: Għandha tingħata kunsiderazzjoni għal amministrazzjoni flimkien ma' aġent antibatteriku ieħor meta jkun possibbli.
English: Polymyxin-based products have been available since the 1960s, but their use quickly decreased due to the availability of antibiotics with fewer potential side effects.
Maltese: Prodotti ibbażati fuq polymyxin ilhom disponibbli sa mis-snin sittin, iżda l-użu tagħhom malajr naqas minħabba d-disponibbilità ta' antibijotiċi b'inqas effetti sekondarji potenzjali.
English: The review of polymyxin-based medicines was initiated on 16 September 2013 at the request of the European Commission, under Article 31 of Directive 2001/83/EC.
Maltese: Ir-reviżjoni ta' mediċini bbażati fuq polymyxin inbdiet fis-16 ta' Settembru 2013 fuq talba talKummissjoni Ewropea, skont Artikolu 31 tad-Direttiva 2001/83/KE. Colistin u l-promediċina colistimethate sodium huma l-uniċi polymyxins approvati għal użu kliniku fl-UE, u r-reviżjoni ġiet limitata għal prodotti użati b'injezzjoni jew bit-teħid tan-nifs (kollha formulati bħala colistimethate sodium ).
English: The Agency's recommendations are based on a review of the available clinical, pharmacological and pharmacokinetic data, although significant gaps still exist, particularly with regard to the pharmacokinetics in special populations such as children and patients with renal impairment.
Maltese: Ir-rakkomandazzjonijiet tal-Aġenzija huma bbażati fuq reviżjoni tad-dejta klinika, farmakoloġika u farmakokinetika disponibbli, għalkemm għadhom jeżistu nuqqasijiet b'mod partikolari fir-rigward talfarmakokinetiċi f'popolazzjonijiet speċjali bħal tfal u adulti b'indeboliment renali.
English: The Committee recommended that doses should always be expressed in international units (IU) but because doses of colistimethate sodium can be expressed in different ways a conversion table should be included in the product information.
Maltese: IlKumitat irrakkomanda li d-dożi għandhom dejjem jiġu espressi f'unitajiet internazzjonali (IU) iżda minħabba li dożi ta' colistimethate sodium jistgħu jiġu espressi b'modi differenti, tabella ta' konverżjoni għandha tiġi inkluża fl-informazzjoni dwar il-prodott.
English: Where appropriate, adult doses of 125,000 IU for intraventricular administration and no more than this for intrathecal administration are recommended.
Maltese: IU għal amministrazzjoni intraventrikulari u xejn iktar minn dan għal amministrazzjoni intratekali huma rakkomandati.
English: • Dosage should be in line with relevant treatment guidelines.
Maltese: • Id-dożaġġ għandu jkun f'konformità mal-linji gwida tal-kura relevanti.
English: • Colistin and colistimethate sodium are older antibiotics (belonging to the class called polymyxins) that are sometimes used for infections that have become resistant to newer treatments.
Maltese: • Colistin u colistimethate sodium huma antibijotiċi eqdem (jappartjenu għall-klassi msejħa polymyxins) li xi drabi jintużaw għal infezzjonijiet li saru reżistenti għal kuri iktar ġodda. Colistimethate sodium jingħata permezz ta' injezzjoni jew ta' inalazzjoni, u jsir colistin ġewwa lġisem.
English: Sevelamer carbonate Winthrop received a marketing authorisation valid throughout the EU on 15 January 2015.
Maltese: Sevelamer carbonate Winthrop rċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fil15 ta' Jannar 2015.
English: (sevelamer carbonate)
Maltese: (karbonat ta' sevelamer)
English: Further information on Sevelamer carbonate Winthrop can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/sevelamer-carbonate-winthrop.
Maltese: ema.europa.eu/medicines/human/EPAR/sevelamer-carbonate-winthrop.
English: Sevelamer carbonate Winthrop is available as tablets (800 mg) and as powder (800 mg and 2.4 g) to be taken 3 times a day with meals.
Maltese: Sevelamer carbonate Winthrop jiġi bħala pilloli (800 mg) u bħala trab (800 mg u 2.4 g) li għandhom jittieħdu tliet darbiet kuljum mal-ikliet.
English: 1 Previously known as Sevelamer carbonate Zentiva.
Maltese: 1Preċedentement magħruf bħala Sevelamer carbonate Zentiva.
English: In two main studies in 110 adults with kidney disease who were on dialysis, Sevelamer carbonate Winthrop brought phosphate levels down to around 1.5-1.6 mmol/l (which is within or close to the normal range) and was as effective as another approved medicine Renagel.
Maltese: F'żewġ studji ewlenin f'110 adult b'mard tal-kliewi li kienu fuq id-dijaliżi, Sevelamer carbonate Winthrop naqqas il-livelli ta' fosfat għal madwar 1.5-1.6 mmol/l (li huwa fil-firxa normali jew qribha) u kien effettiv daqs Renagel, li hija mediċina oħra approvata.
English: Sevelamer carbonate Winthrop
Maltese: Informazzjoni oħra dwar Sevelamer carbonate Winthrop
English: It contains the active substance sevelamer carbonate.
Maltese: Fih is-sustanza attiva karbonat ta' sevelamer.
English: Sevelamer carbonate Winthrop is a medicine used to control hyperphosphataemia (high blood phosphate levels) in:
Maltese: Sevelamer carbonate Winthrop huwa mediċina użata biex tikkontrolla l-iperfosfatemija (livelli għoljin ta' fosfat fid-demm):
English: In a third main study in 49 adults who were not on dialysis, Sevelamer carbonate Winthrop reduced phosphate levels from 2.0 mmol/l to 1.6 mmol/l.
Maltese: Fit-tielet studju ewlieni f'49 adult li ma kinux fuq id-dijaliżi, Sevelamer carbonate Winthrop naqqas illivelli ta' fosfat minn 2.0 mmol/l għal 1.6 mmol/l.
English: • adults and children from 6 years of age with chronic (long-term) kidney disease.
Maltese: • f'adulti u fi tfal li għandhom aktar minn 6 snin b'marda kronika (fit-tul) tal-kliewi.
English: The active substance in Sevelamer carbonate Winthrop, sevelamer carbonate, is a phosphate binder.
Maltese: Is-sustanza attiva f'Sevelamer carbonate Winthrop, il-karbonat ta' sevelamer, teħel mal-fosfat.
English: Finally, a main study also showed that Sevelamer carbonate Winthrop was effective at lowering phosphate levels in 100 children: children who took Sevelamer carbonate Winthrop had a greater reduction in phosphorous (0.87 mg/dl) than those taking placebo (a dummy treatment) who had a rise in phosphorous of 0.04 mg/dl.
Maltese: Fl-aħħar nett, studju ewlieni wera wkoll li Sevelamer carbonate Winthrop kien effettiv biex inaqqas illivelli tal-fosfat f'100 tifel u tifla: tfal li ħadu Sevelamer carbonate Winthrop kellhom tnaqqis akbar filfosfru (0.87 mg/dl) minn dawk li kienu qed jieħdu plaċebo (kura finta) li kellhom żieda fil-fosfru ta' 0.04 mg/dl.
English: • adult patients on dialysis (a technique to remove unwanted substances from the blood);
Maltese: • f'pazjenti adulti fuq id-dijaliżi (teknika biex jitneħħew sustanzi mhux mixtieqa mid-demm);
English: Why is Sevelamer carbonate Winthrop approved?
Maltese: Għaliex ġie approvat Sevelamer carbonate Winthrop?
English: For the full list of side effects of Sevelamer carbonate Winthrop, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji ta' Sevelamer carbonate Winthrop, ara lfuljett ta' tagħrif.
English: What are the risks associated with Sevelamer carbonate Winthrop?
Maltese: X'inhuma r-riskji assoċjati ma' Sevelamer carbonate Winthrop?